Clinical bottom line
Early initiation of personalized antiplatelet therapy guided by platelet function testing (PFT), with or without pharmacogenomic profiling, is a promising strategy to optimize dual antiplatelet therapy (DAPT) in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI). Emerging evidence suggests that tailoring therapy based on platelet reactivity or CYP2C19 genotype may reduce ischemic events and bleeding complications in selected high-risk populations. However, the clinical benefit remains modest and heterogeneous across studies, and routine implementation is not yet standard of care. Personalized antiplatelet therapy warrants further validation in large, prospective trials before widespread adoption.
What the evidence shows
Platelet function testing and genotyping have been explored as tools to individualize antiplatelet therapy in ACS, aiming to balance thrombotic risk reduction against bleeding risk. Lei Mengjie et al. (2026) reported that PFT-guided DAPT in dual high-risk ACS patients undergoing PCI was associated with improved prognosis, including reduced major adverse cardiovascular events (MACE), compared to standard therapy. This suggests that early PFT can identify patients with high on-treatment platelet reactivity who may benefit from intensified or alternative antiplatelet regimens.
Similarly, pharmacogenomic testing, particularly CYP2C19 genotyping, has been shown to influence clopidogrel metabolism and clinical outcomes. Jiang Minghuan et al. (2015) demonstrated that combining CYP2C19 genotype with platelet reactivity to guide antiplatelet therapy improved outcomes in ACS patients, reducing ischemic events without increasing bleeding. Massmann et al. (2024) further supported the clinical impact of preemptive pharmacogenomic testing in real-world settings, highlighting its potential to optimize antiplatelet selection.
Venissa Rebello Jeenal et al. (2026) provided a comprehensive scoping review emphasizing that both PFT and genotyping can guide personalized therapy, but the evidence is mixed regarding which approach is superior or whether combined strategies offer additive benefit. Li Jing et al. (2018) discussed practical considerations for selecting antiplatelet agents based on PFT or genotyping, underscoring the need for individualized assessment rather than a one-size-fits-all approach.
Cohoon Kevin P et al. (2013) reviewed the clinical utility of PFT in guiding therapy post-PCI or in ACS, concluding that while PFT identifies patients at risk of adverse events, evidence for improved clinical outcomes with PFT-guided therapy remains inconclusive. Panzer Benjamin et al. (2022) added that patient factors such as body size may influence platelet function and response to therapy, suggesting further complexity in personalizing treatment.
Caveats and uncertainty
Despite encouraging data, several caveats limit the routine use of early PFT-guided personalized antiplatelet therapy in ACS:
- Heterogeneity in PFT methods, timing, and thresholds complicates standardization and interpretation across centers.
- Most studies are observational or relatively small; large randomized controlled trials with hard clinical endpoints are limited.
- The incremental benefit of combining PFT with pharmacogenomic testing versus either alone is unclear.
- Patient populations studied often exclude those at extreme bleeding or ischemic risk, limiting generalizability.
- Cost-effectiveness and logistical feasibility of routine PFT and genotyping remain concerns.
- Some guidelines currently recommend against routine PFT-guided therapy due to insufficient evidence for improved outcomes.
How this may change practice
Clinicians managing ACS patients undergoing PCI should be aware of the evolving evidence supporting personalized antiplatelet therapy guided by platelet function and/or genotype testing. In select high-risk patients—such as those with recurrent ischemic events, high on-treatment platelet reactivity, or known CYP2C19 loss-of-function alleles—early testing may inform tailored therapy choices, potentially improving outcomes.
However, widespread adoption requires further validation from large-scale randomized trials demonstrating clear net clinical benefit and cost-effectiveness. Until then, PFT and pharmacogenomic testing should be considered adjunctive tools rather than routine standard of care, used in multidisciplinary decision-making where available and appropriate.
Future research should focus on harmonizing testing protocols, identifying patient subgroups most likely to benefit, and integrating personalized antiplatelet strategies into clinical pathways to optimize safety and efficacy.